SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves quarterly results beat expectations, with raised guidance and a larger AI-compute backlog drawing attention; traders also focused on managements financing plans and expected customer prepayments. Bulls said the update eased funding concerns, while bears remained wary of heavy debt, spending and interest costs, contributing to a muted, volatile reaction.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists Q3 results and outlook are driving attention, with traders focused on Samsung and Micron licensing revenue, improved profitability, and expected contributions from Micron and product sales in the next quarter. Many are bullish on the stronger financial position, while others question the decline in product sales and note that a SK hynix deal or Nasdaq uplisting remains unconfirmed speculation.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders parsing the earnings-call comments for clues about the review and possible labeling. Many are optimistic about approval and launch readiness, while others stress the uncertainty following the advisory panels negative vote; the post-earnings selloff has added to the debate.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias selloff is drawing attention amid a board investigation into CEO Jensen Huangs relationship with an executive linked to alleged chip shipments to China, alongside shareholder-litigation and disclosure concerns; the allegations remain unproven. Traders are divided between fears of governance, export-control and succession risks and the view that the controversy is an overreaction and a buying opportunity.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigettis Q3 results missed revenue and adjusted-loss expectations, with its outlook adding to concerns about commercialization and valuation. Many traders are bearish on the companys limited current sales and cash burn, while some remain bullish on its quantum-technology progress and long-term potential.

Pepe (PEPE) is a cryptocurrency launched in 2023and operates on the Ethereum platform. Pepe has a current supply of 413,772,350,095,630.40630647. The last known price of Pepe is 0.00000511 USD and is up 0.93 over the last 24 hours. It is currently trading on 729 active market(s) with $552,678,948.79 traded over the last 24 hours. More information can be found at https://www.pepe.vip/.

Pepe

A volatile PEPE rebound and perceived strength versus a weak broader crypto market are drawing attention, with traders cheering renewed buying and a possible breakout. Others warn that rallies have repeatedly faded and view the price action as fragile or a potential bull trap.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costcos announced special cash dividend and renewed stock-buyback authorization are driving attention, with traders welcoming the shareholder returns and some cautioning that the ex-dividend price adjustment is not a free gain. Discussion also reflects debate over whether the stocks premium valuation is justified.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPaths fiscal Q1 results are driving discussion: revenue fell short of expectations while EPS beat, and traders are weighing the revenue miss against stronger margins, a record backlog and defense-order growth. Reactions are mixed, with optimism about demand and future deliveries tempered by concerns over supply-chain delays and whether the company can convert its backlog into revenue.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumbles Q3 earnings report is the main focus, with traders weighing expected growth from its Quake AI/Northern Data business against ongoing losses and uncertainty over data-center financing and the reported Anthropic contract. Bulls anticipate a strong report and possible short-covering, while skeptics doubt that revenue growth will resolve funding, dilution, and execution concerns.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Strong Q3 revenue growth and another increase to full-year guidance sparked a sharp rally in Senseonics, but shares gave back much of the move as traders took profits. Bulls point to accelerating Eversense adoption, while skeptics remain concerned about cash burn, dilution and whether the growth can be sustained.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Continue to Hold TMO Stock in Your Portfolio?

Thermo Fisher's accelerating organic growth, rising bioproduction demand and strong capital returns support its outlook, but macroeconomic risks and competition remain concerns.

Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized the repurchase of up to an aggregate of $5 billion of shares of its common stock in the open market or in negotiated transactions. The authorization has no...

Thermo Fisher Scientific Announces Quarterly Dividend

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on January 15, 2027, to shareholders of record as of December 15, 2026. About Thermo Fisher Scientific...

$100 Invested In Thermo Fisher Scientific 10 Years Ago Would Be Worth This Much Today

Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 10 years by 2.78% on an annualized basis producing an average annual return of 16.17%. Currently, Thermo Fisher Scientific has a marketread more...

If You Invested $1000 in Thermo Fisher Scientific a Decade Ago, This is How Much It'd Be Worth Now

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Beat the Market Like Zacks: Marathon Petroleum, Amgen, Chevron in Focus

Zacks highlights MPC, AMGN and CVX as standout performers, with strong returns across its stock recommendations and model portfolios despite market volatility.

RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs

ResMed's first-quarter fiscal 2027 earnings and revenues top estimates as sustained sleep device demand, productivity gains and gross margin expansion drive growth.

Top Research Reports for Alphabet, ExxonMobil & Toyota Motor

Alphabet, ExxonMobil and Toyota Motor headline today's top research reports, highlighting AI growth, energy cash generation and hybrid vehicle opportunities.

Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors

Key PointsThermo Fisher raised its 2026 organic revenue growth outlook to 4...

Nasdaq Gains 1%; Thermo Fisher Scientific Posts Upbeat Earnings

U.S. stocks rose Wednesday, led by Nasdaq (+1.06%) and tech. Thermo Fisher beat estimates and raised guidance; oil fell, gold edged higher.read more...

• Reported GAAP EPS of $6.68 up 15.37% YoY
• Reported revenue of $12.14B up 9.13% YoY

Thermo Fisher Scientific reported Specialty Diagnostics revenue of $1.1B versus $1.17B, long-term obligations of $39.11B versus $35.85B, and dependence on customer capital spending and government funding policies.

Thermo Fisher Scientific's adjusted operating income was $2.97B, 15% higher than the year-ago quarter; its Ion 560 Chip offers nearly twice the prior offering's sequencing capacity, and Precure launched with Mayo Clinic.

Thermo Fisher Scientific Inc. offers products and services to customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment provides reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines, and diagnosis of disease. The Analytical Instruments segment offers instruments and supporting consumables, software and services. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments and associated products to healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. The Laboratory Products and Biopharma Services segment offers outsourced services used by the pharmaceutical and biotech industries for drug development, clinical research, clinical trials services and commercial drug manufacturing. The company was founded in July 1956 and is headquartered in Waltham, MA.

Thermo Fisher Scientific Inc.

Thermo Fisher CEO Says AI Will Drive More Pharma Spending — Sees 7% Organic Growth By 2028

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Casper said Thermo Fisher expects organic growth of about 4% in the second half of 2026.</li><li>The CEO said drugmakers could spend more to test promising medicines across more diseases.</li><li>Thermo Fisher has a partnership with OpenAI to speed up clinical trials and drug development.</li></ul>Thermo Fisher Scientific (TMO) CEO Marc Casper said artificial intelligence could ultimately increase spending across the pharmaceutical industry rather than reduce demand for laboratory research.In an interview with CNBC on Tuesday, Casper said AI is helping drugmakers identify ineffective drugs quicker while also accelerating the development of promising therapies.“AI is helping kill ineffective medicines faster, so that you don’t spend money on things that don’t work, and at the same point in time, shorten the time to market for those things that do work, and that gives you a longer return cycle on an improved medicine, and that will spur more investments,” Casper said.At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/TMO">TMO stock</a> was up 4%, heading for a third straight session of gains.<h2 class="st-heading-2">AI Could Spur More Drug Research Investments</h2>Casper pushed back on concerns that AI could reduce the need for laboratory experiments as drug research increasingly moves online.“So when you have more insights into what you do, you actually do a lot more validation, because what you’ll then do is spend more money on the ultimate number of indications or types of disease you’re going after with the medicine. So, AI - more spending, not less spending,” Casper addedThermo Fisher previously said AI could improve returns from drug discovery and encourage customers to invest more money into their pipelines. The company is also integrating AI into its operations, including a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.thermofisher.com/investors/news-events/news/news-details/2025/Thermo-Fisher-Scientific-to-Accelerate-Life-Science-Breakthroughs-with-OpenAI/default.aspx?">collaboration</a> with OpenAI to speed up clinical trials and drug development.<h2 class="st-heading-2">Thermo Fisher’s 7% Organic Growth Target By 2028</h2>Casper said Thermo Fisher expects organic growth of about 4% in the second half of 2026 before accelerating to 7% by 2028. The outlook reflects improving momentum in the second quarter, when Thermo Fisher’s revenue <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2026/Thermo-Fisher-Scientific-Reports-Second-Quarter-2026-Results/default.aspx">rose</a> 10% to $11.99 billion, with organic revenue up 5%.“I actually think the organic story, going forward, is very good,” Casper said.<h2 class="st-heading-2">Retail’s Take On TMO</h2>Retail sentiment surrounding TMO on Stocktwits remained in the ‘bearish’ zone over the past 24 hours.TMO shares have gained more than 9% in 2026.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/way-stock-surges-on-reported-sale-buzz-rbc-flags-this-tech-giant-as-the-obvious-first-name/cZtnWoERBc1">&nbsp;WAY Stock Surges On Reported Sale Buzz — RBC Flags This Tech Giant As The ‘Obvious First Name’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Thermo Fisher Scientific raised its full-year adjusted EPS guidance to a new range of $21.35 to $22.07 | Image Source: Thermo Fisher

In an interview with CNBC on Tuesday, Marc Casper said AI is helping drugmakers identify ineffective medicines quicker while also shortening the time to market for promising therapies.

Yes, by year-end

Yes, but not this year

No, he stays as CEO

He steps down on his own

Do you think Jensen Huang will be removed as Nvidia’s ($NVDA) CEO?

Stocktwits

Do you think Jensen Huang will be removed as Nvidia’s (

Feed

News

Sentiment

Earnings

Fundamentals

Info

TMO News